Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 3,520 Shares

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 3,520 shares of Phibro Animal Health stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $41.15, for a total transaction of $144,848.00. Following the sale, the chief executive officer owned 48,800 shares in the company, valued at approximately $2,008,120. The trade was a 6.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Jack Bendheim also recently made the following trade(s):

• On Tuesday, February 3rd, Jack Bendheim sold 9,660 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.47, for a total transaction of $400,600.20.
• On Friday, January 30th, Jack Bendheim sold 6,693 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total transaction of $268,322.37.
• On Thursday, January 29th, Jack Bendheim sold 6,772 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.12, for a total value of $271,692.64.
• On Friday, January 23rd, Jack Bendheim sold 1,235 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.55, for a total value of $50,079.25.
• On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.98, for a total value of $552,372.84.
• On Wednesday, January 21st, Jack Bendheim sold 14,687 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.68, for a total value of $612,154.16.
• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.02, for a total value of $117,338.64.
• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.53, for a total transaction of $147,975.03.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.32, for a total transaction of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.16, for a total transaction of $8,554.08.

Phibro Animal Health Price Performance

Shares of NASDAQ:PAHC traded up $9.00 on Thursday, reaching $50.00. The company’s stock had a trading volume of 981,708 shares, compared to its average volume of 238,086. The company has a 50-day simple moving average of $39.88 and a 200 day simple moving average of $38.14. Phibro Animal Health Corporation has a 52-week low of $16.16 and a 52-week high of $50.05. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.35 and a current ratio of 3.09. The company has a market cap of $2.03 billion, a P/E ratio of 30.12, a PEG ratio of 1.17 and a beta of 0.80.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.18. The firm had revenue of $373.91 million during the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. As a group, equities research analysts anticipate that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Wednesday, March 4th will be given a dividend of $0.12 per share. The ex-dividend date is Wednesday, March 4th. This represents a $0.48 dividend on an annualized basis and a yield of 1.0%. Phibro Animal Health’s payout ratio is 28.92%.

Wall Street Analysts Forecast Growth

PAHC has been the subject of several analyst reports. JPMorgan Chase & Co. raised their price objective on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. Finally, Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Phibro Animal Health presently has a consensus rating of “Hold” and an average price target of $31.40.

Key Stories Impacting Phibro Animal Health

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Q2 results beat expectations — Phibro reported $0.87 EPS vs. consensus ~$0.69 and revenue of $373.9M vs. ~$355.6M, showing 21% year-over-year sales growth and a jump in net income. This beats drove the immediate market reaction. Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
• Positive Sentiment: FY2026 guidance raised — management set full-year EPS guidance of $2.930–$3.100, above street consensus (about $2.75), and reiterated ~ $1.5B revenue guidance; the stronger EPS range is a primary bullish catalyst. Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
• Positive Sentiment: Operational momentum highlighted — company disclosed improved margins, return on equity, and year-over-year net income growth (net income rose materially vs. prior year), supporting the upgraded guidance. Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
• Neutral Sentiment: Full earnings materials published — the Q2 earnings call transcript and slide presentation are available for detailed read-throughs of segment trends, margin drivers and FX/commodity commentary (useful for assessing sustainability of the beat). Phibro Animal Health Corporation (PAHC) Q2 2026 Earnings Call Transcript Phibro Animal Health Corporation 2026 Q2 – Results – Earnings Call Presentation
• Neutral Sentiment: Dividend declared — board announced a $0.12 quarterly dividend (record/ex-dividend dates set), modestly supportive for income-focused holders but not a major catalyst.
• Negative Sentiment: Insider selling — filings show director Jack Bendheim sold multiple blocks of shares this reporting window; market interprets insider selling as a mild negative signal to weigh against the positive results. Jack Bendheim Sells 6,693 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock Jack Bendheim Sells 6,772 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock
• Negative Sentiment: Mixed/contradictory analyst and press coverage — some outlets flagged skepticism or pessimistic takes ahead/around the print, creating short-term volatility risk despite the beat; monitor follow-up analyst revisions. Zacks Research Has Pessimistic Outlook of PAHC Q2 Earnings

Institutional Trading of Phibro Animal Health

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in shares of Phibro Animal Health by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company’s stock worth $57,519,000 after acquiring an additional 13,884 shares during the last quarter. Geode Capital Management LLC increased its stake in Phibro Animal Health by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 554,927 shares of the company’s stock valued at $14,175,000 after purchasing an additional 7,841 shares in the last quarter. Millennium Management LLC increased its stake in Phibro Animal Health by 74.3% during the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock valued at $7,733,000 after purchasing an additional 154,281 shares in the last quarter. Ranger Investment Management L.P. raised its holdings in shares of Phibro Animal Health by 101.1% in the second quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock worth $9,143,000 after buying an additional 179,975 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Phibro Animal Health by 22.5% during the third quarter. Invesco Ltd. now owns 322,299 shares of the company’s stock worth $13,040,000 after buying an additional 59,226 shares during the period. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.